The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
Abstract
BACKGROUND: Progressive subcutaneous fat wasting, fat accumulation, dyslipidaemia and insulin resistance in HIV-infected patients on antiretroviral therapy has been attributed to the long-term toxicity of HIV protease inhibitors (PI). More recently, fat wasting has been observed in patients who have never taken a PI, implicating an independent effect of nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy. OBJECTIVES: To determine the relative contribution of NRTI and PI, as well as any other factors, to fat wasting in HIV-infected patients. DESIGN: Longitudinal cohort study involving 277 participants of the Western Australian HIV Cohort Study. METHODS: The time to onset of clinically apparent fat wasting in patients receiving different antiretroviral regimens was compared using standardized clinical criteria. Regional fat measured by dual energy X-ray absorptiometry (DEXA) in 161 patients was also compared. The average rate of percentage fat reduction was estimated in 70 patients who had consecutive DEXA scans at approximately 6-monthly intervals. Multiple confounding factors were considered in the analyses. RESULTS: Progressive subcutaneous fat wasting, indistinguishable from that described in PI-treated patients, does occur in PI-naive, NRTI-treated patients. In patients taking triple combination antiretroviral therapy, age (relative risk = 1.052 per year; P < 0.0001), white race (relative risk = 3.9; P = 0.023), longer duration of dual NRTI therapy prior to addition of PI (relative risk = 1.021 per month; P = 0.0046) and increased cumulative time on stavudine-containing regimens compared with time on zidovudine-containing regimens (relative risk = 1.085 per month; P < 0.0001) are associated with increased risk of fat wasting. Stavudine increases the risk of fat wasting by 265% per year compared with zidovudine. However PI therapy is associated with faster progression to clinically apparent wasting compared with dual NRTI therapy without PI. The results of DEXA scanning supports these clinical data and suggest a non-linear decline in fat over time. CONCLUSIONS: NRTIs do have an independent contribution to fat wasting, but PI are the predominant influence and may act synergistically with NRTIs. NRTIs appear to predispose individuals to slowly progressive fat loss, which is markedly accelerated when a PI and NRTIs are combined. Of the NRTIs, stavudine leads to an earlier onset of clinically apparent fat wasting compared with zidovudine. Fat wasting associated with NRTI use may be a manifestation of mitochondrial toxicity, which may be exacerbated by PI use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · cited 2×
“The lipodystrophy syndrome was ascribed to a unique cumulative toxicity of HIV protease inhibitor (PI) therapy [2,4] having been noted only 2 years after the introduction of PI into routine”
BackgroundAdverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Mitochondrial toxicity of antiviral drugs
Lewis, W., & Dalakas, M. C. (1995) · Nature Medicine · doi:10.1038/nm0595-417 · Cited by 770
Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J.-M., Gastaut, J.-A., & Touraine, J.-L. (1999) · AIDS · doi:10.1097/00002030-199909100-00009 · Cited by 581
Hirano, M., Silvestri, G., Blake, D. M., Lombes, A., Minetti, C., Bonilla, E., Hays, A. P., Lovelace, R. E., Butler, I., Bertorini, T. E., et al. (1994) · Neurology · doi:10.1212/wnl.44.4.721 · Cited by 405
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
Gervasoni, C., Ridolfo, A. L., Trifirò, G., Santambrogio, S., Norbiato, G., Musicco, M., Clerici, M., Galli, M., & Moroni, M. (1999) · Aids · doi:10.1097/00002030-199903110-00004 · Cited by 298
Indinavir-associated lipodystrophy
Viraben, R., & Aquilina, C. (1998) · AIDS · doi:10.1097/00002030-199806000-00001 · Cited by 271
Lipodystrophy in patients naive to HIV protease inhibitors
Madge, S., Kinloch-de-Loes, S., Mercey, D., Johnson, M. A., & Weller, I. V. D. (1999) · AIDS · doi:10.1097/00002030-199904160-00020 · Cited by 185
Cited by
Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
Carr, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12656-6 · Cited by 422
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Carr, A. (2002) · JAMA · doi:10.1001/jama.288.2.207 · Cited by 300
Metadata
- Authors
- Mallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J.
- Venue
- AIDS
- Published
- 2000-07
- Volume
- 14
- Issue
- 10
- Pages
- 1309-1316
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2024720867
- Cited by
- 510
- References
- 16
- FWCI
- 58.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. https://app.cochat.ai/papers/10.1097/00002030-200007070-00002
- The paper
- Mallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000). Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. https://doi.org/10.1097/00002030-200007070-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.